Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Characteristics of patients with androgen-sensitive, oligometastatic prostate cancer (Oli-P study cohort) that received ablative radiotherapy with curative intend to metastatic lesions. Patients were treated at the Department of Radiotherapy and Radiation Oncology of the University Hospital Carl Gustav Carus, Dresden (ClinicalTrials.gov Identifier: NCT02264379) between 2014 and 2021

From: Blood-based detection of MMP11 as a marker of prostate cancer progression regulated by the ALDH1A1-TGF-β1 signaling mechanism

Parameter

Number of patients

%

ISUP grade

 High (≥ 4)

10/31

32%

NCCN risk group

 Low

0/31

0%

 Intermediate

9/31

29%

 High, very high, local advanced

22/31

71%

Metastases

 Lymph node

21/31

68%

 Bone

6/31

19%

 Both

4/31

13%

Radiotherapy to metastases

 Normo-fractionation (25 × 2 Gy)

7/31

23%

 Hypo-fractionation (3 × 10 Gy)

24/31

77%

Parameter

Mean

Range

Age (years)

73

53–84

Gross tumor volume (GTV) (ccm)

3.0

0.1–11.0

PSA before radiotherapy (ng/ml)

3.02

0.69–8.78

  1. GTV Gross tumor volume; the sum of one to three metastatic lesions, ISUP International Society of Urological Pathology, NCCN National Comprehensive Cancer Network